Spotlight Commentary: A post approval look at anticoagulants

Spotlight—Introducing a new Commentary series for the BJCP

“…Li Wei and Adam Cohen are joined by Anthonius de Boer on another Commentary, “A post approval look at anticoagulants”, and engage with the pharmaco‐epidemiological challenge of correctly identifying and ascribing rarer adverse events. Three papers using different approaches (eg, controlling for potential bias and different populations) are described—resulted in different associations of the newer direct acting anticoagulants (DOACs), and the vitamin K antagonists with bleeding and thrombotic events.…”